Biofilm formation and increased mortality among cancer patients with candidemia in a Peruvian reference center

• Published in: BMC infectious diseases Vol. 24; no. 1; pp. 1145 - 15
• Main Authors: Villanueva-Cotrina, Freddy, Bejar, Vilma, Guevara, José, Cajamarca, Ines, Medina, Cyntia, Mujica, Luis, Lescano, Andres G
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 12-10-2024; BioMed Central; BMC
• Subjects: Adult; Aged; Antifungal agents; Antifungal Agents - therapeutic use; Antimicrobial agents; Argentina; Biofilms; Biofilms - growth & development; Bivariate analysis; Cancer; Cancer patients; Candida - drug effects; Candida - isolation & purification; Candida - physiology; Candidemia; Candidemia - drug therapy; Candidemia - microbiology; Candidemia - mortality; Candidiasis; Care and treatment; Catheters; Comorbidity; Control; Death; Diagnosis; Drug therapy; Emergency medical services; Fatalities; Female; Fungicides; Health services; Hospitals; Humans; Identification and classification; Laboratories; Male; Medical records; Methods; Microbial mats; Microbiology; Middle Aged; Mortality; Mycosis; Neoplasms - complications; Neoplasms - microbiology; Neoplasms - mortality; Neutropenia; Nosocomial infections; Patient outcomes; Patients; Peru - epidemiology; Phlebotomy; Prevention; Retrospective Studies; Risk; Risk factors; Sample size; Statistical analysis; Survival analysis; Peru; Argentina; United States > US; Biofilms; Candidemia; Mortality; Risk factors; Cancer
• ISSN: 1471-2334; 1471-2334
• DOI: 10.1186/s12879-024-10044-5

Candidemia is an invasive mycosis with an increasing global incidence and high mortality rates in cancer patients. The production of biofilms by some strains of Candida constitutes a mechanism that limits the action of antifungal agents; however, there is limited and conflicting evidence about its role in the risk of death. This study aimed to determine whether biofilm formation is associated with mortality in cancer patients with candidemia.
This retrospective cohort study included patients treated at Peru's oncologic reference center between June 2015 and October 2017. Data were collected by monitoring patients for 30 days from the diagnosis of candidemia until the date of death or hospital discharge. Statistical analyses evaluated the association between biofilm production determined by XTT reduction and mortality, adjusting for demographic, clinical, and microbiological factors assessed by the hospital routinary activities. Survival analysis and bivariate and multivariate Cox regression were used, estimating the hazard ratio (HR) as a measure of association with a significance level of p < 0.05.
A total of 140 patients with candidemia were included in the study. The high mortality observed on the first day of post-diagnosis follow-up (81.0%) among 21 patients who were not treated with either antifungal or antimicrobial drugs led to stratification of the analyses according to whether they received treatment. In untreated patients, there was a mortality gradient in patients infected with non-biofilm-forming strains vs. low/medium and high-level biofilm-forming strains (25.0%, 66.7% and 82.3%, respectively, p = 0.049). In treated patients, a high level of biofilm formation was associated with increased mortality (HR, 3.92; 95% p = 0.022), and this association persisted after adjusting for age, comorbidities, and hospital emergency admission (HR, 6.59; CI: 1.87-23.24, p = 0.003).
The association between candidemia with in vitro biofilm formation and an increased risk of death consistently observed both in patients with and without treatment, provides another level of evidence for a possible causal association. The presence of comorbidities and the origin of the hospital emergency, which reflect the fragile clinical condition of the patients, and increasing age above 15 years were associated with a higher risk of death.